GlobeNewswire: Tecan schliesst die Platzierung von 650,000 neuen Aktien und damit den ersten Schritt zur teilweisen Refinanzierung der Übernahme der Paramit Corporation erfolgreich ab

Tecan schliesst die Platzierung von 650,000 neuen Aktien und damit den ersten Schritt zur teilweisen Refinanzierung der Übernahme der Paramit Corporation erfolgreich ab NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Ad-hoc-Mitteilung gemäss Artikel 53 des Kotierungsreglements der SIX Exchange Regulation Männedorf, Schweiz, 3 . September 2021 – Die Tecan Group AG («Tecan Group» oder «Tecan», SIX Swiss Exchange: TECN) hat erfolgreich 650,000 neue Namenaktien (die «Neuen Aktien») mit einem Nennwert von je CHF 0.10 im Rahmen einer Aktienplatzierung mittels Accelerated-Bookbuilding-Verfahrens platziert (die «Aktienplatzierung»). Der Ausgabepreis wurde auf CHF 550 pro Aktie festgelegt und der Bruttoerlös aus der Aktienplatzierung beläuft sich auf CHF 357.5 Mio. Der Nettoerlös aus der Aktienplatzierung wird zur teilweisen Refinanzierung der Akquisition der Paramit Corporation (die «Akquisition») verwendet. Die Neuen Aktien, die ca. 5.4% des derzeit ausgegebenen, registrierten Aktienkapitals von Tecan entsprechen, werden aus dem bestehenden genehmigten Aktienkapital von Tecan ausgegeben. Das Bezugsrecht für bestehende Aktionäre wurde ausgeschlossen. Die Neuen Aktien werden voraussichtlich am 7. September 2021 an der SIX Swiss Exchange kotiert und zum Handel zugelassen. Zahlung und Abwicklung werden voraussichtlich am 7. September 2021 erfolgen. Die Neuen Aktien werden gleichrangig mit den bestehenden Aktien sein. Im Rahmen der Aktienplatzierung hat Tecan einer Ausgabe- und Verkaufssperrfrist von 180 Tagen nach der Kotierung der Neuen Aktien zugestimmt, vorbehaltlich üblicher Ausnahmen. Über Tecan Tecan (www.tecan.com) ist ein weltweit führender Anbieter von Laborinstrumenten und Lösungen für die Branchen Biopharma, Forensik und Klinische Diagnostik. Das Unternehmen ist auf Entwicklung, Herstellung und Vertrieb von Automatisierungslösungen für Laboratorien im Life-Science-Bereich spezialisiert. Die Kunden von Tecan sind Pharma- und Biotechnologieunternehmen, Forschungsabteilungen von Universitäten sowie forensische und diagnostische Laboratorien. Als Originalgerätehersteller (OEM) ist Tecan auch führend in der Entwicklung und Herstellung von OEM-Instrumenten und Komponenten, die vom jeweiligen Partnerunternehmen vertrieben werden. Tecan wurde 1980 in der Schweiz gegründet. Das Unternehmen verfügt über Produktions-, Forschungs- und Entwicklungsstätten in Europa und in Nordamerika. In 52 Ländern unterhält es ein Vertriebs- und Servicenetz. Im Jahr 2020 erzielte Tecan einen Umsatz von CHF 731 Mio. (USD 778 Mio.; EUR 683 Mio.). Die Namenaktien der Tecan Group werden an der SIX Swiss Exchange gehandelt (TECN; ISIN CH0012100191). Weitere Auskünfte: Tecan Group Martin Brändle Senior Vice President, Corporate Communications & IR Tel. +41 (0) 44 922 84 30 Fax +41 (0) 44 922 88 89 investor@tecan.com www.tecan.com This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. This document is not a prospectus within the meaning of Article 35 et seqq. or 69 of the Swiss Federal Act on Financial Services and not a prospectus under any other applicable laws. The offer and listing of the Securities will be made without the publication of a prospectus in reliance on the exemptions provided in article 36 paragraph 1 letter a and article 38 paragraph 1 letter a of the Financial Services Act. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. This document is not for publication or distribution in the United States of America (including its territories and possessions, any State of the United States and the District of Columbia), Canada, Australia or Japan or any other jurisdiction into which the same would be unlawful. This document does not constitute an offer or invitation to subscribe for or purchase any securities into the United State or in such countries or in any other jurisdiction into which the same would be unlawful. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States of America or to publications with a general circulation in the United States of America. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the 'Securities Act'), or the laws of any state, and may not be offered or sold in the United States of America absent registration under or an exemption from registration under the Securities Act. There will be no public offering of the securities in the United States of America. The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'FSMA Order') or (iii) persons falling within Articles 49(2)(a) to (d), 'high net worth companies, unincorporated associations, etc.' of the FSMA Order, and (iv) persons to whom an invitation or inducement to engage in investment activity within the meaning of Section 21 of the Financial Services and Markets Act 2000 may otherwise be lawfully communicated or caused to be communicated (all such persons together being referred to as 'relevant persons'). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Any offer of securities to the public that may be deemed to be made pursuant to this communication in any EEA member state is only addressed to qualified investors in that member state within the meaning of Regulation (EU) 2017/1127 and such other persons as this document may be addressed on legal grounds, and no person that is not a relevant person or a qualified investor may act or rely on this document or any of its contents. This publication may contain specific forward-looking statements, e.g. statements including terms like 'believe', 'assume', 'expect', 'forecast', 'project', 'may', 'could', 'might', 'will' or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Tecan Group AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Tecan Group AG assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Except as required by applicable law, Tecan Group AG has no intention or obligation to update, keep updated or revise this publication or any parts thereof (including any forward-looking statement) following the date hereof. None of the underwriters or any of their respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents, alliance partners or any other entity or person accepts any responsibility or liability whatsoever for, or makes any representation, warranty or undertaking, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the group, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith. Accordingly, each of the underwriters and the other foregoing persons disclaim, to the fullest extent permitted by applicable law, all and any liability, whether arising in tort or contract or that they might otherwise be found to have in respect of this announcement and/or any such statement. Anhang Medienmitteilung